BACKGROUND: Lost bone in @entity3604 @entity1 increases the risk of @entity174 and @entity615 , and decreases quality of life. The aim of this study was to analyse the effect of teriparatide (TPTD) in @entity3604 @entity1 with @entity158 . METHODS: A prospective observational study between April 2006 and February 2014 was done with 77 @entity1 treated with teriparatide in the @entity158 Unit of Hospital Obispo Polanco of Teruel (Spain). Treatment duration was 18 or 24 months. @entity158 was assessed by the Visual Analogue Scale (VAS). Health-related quality of life was measured using the European Quality of Life Questionnaire (EuroQol-5D) in order to obtain the social tariff (ST). Pre and post-treatment values were collected respectively. A descriptive and regression analysis was done. RESULTS: Improvement in @entity158 was observed (80%) and in health-related quality of life (65%). The mean VAS improved (from 5.42 to 3.47 points) and the mean health status value too (from 0.36 to 0.58 points). The regression indicated an improvement of VAS in 0.441 for each initial VAS point, and of ST in 0.0528 points for each 0.1 initial ST point. The probability of VAS reduction in 3 points (OR = 2.021) was greater than in 2 points (OR = 1.695). CONCLUSIONS: TPTD reduces @entity158 and improves quality of life of @entity3604 @entity1 . The worse the baseline situation, the more @entity1 ' health improved, so it could be used as criteria for therapeutic decisions and health management.

[Impact of Teriparatide on Quality of Life in Osteoporotic XXXX ].

@entity3604 :: ('MESH:D058866', 'Disease') :: ['osteoporotic'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures'] @entity615 :: ('MESH:D001416', 'Disease') :: ['back pain'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'vertebral pain', 'pain']
@entity1 :: (9606,Species) :: ['Patients']
